Related Experiment Video
Updated: Jun 23, 2025
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Melanoma Management: Exploring Staging, Prognosis, and Treatment Innovations
Walid Shalata1,2, Zoe Gabrielle Attal3, Adam Solomon3
1The Legacy Heritage Cancer Center and Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel.
Abstract:
Melanoma, a malignant neoplasm originating from melanocytes, stands as one of the most prevalent cancers globally, ranking fifth in terms of estimated new cases in recent years. Its aggressive nature and propensity for metastasis pose significant challenges in oncology. Recent advancements have led to a notable shift towards targeted therapies, driven by a deeper understanding of cutaneous tumor pathogenesis. Immunotherapy and tyrosine kinase inhibitors have emerged as promising strategies, demonstrating the potential to improve clinical outcomes across all disease stages, including neoadjuvant, adjuvant, and metastatic settings. Notably, there has been a groundbreaking development in the treatment of brain metastasis, historically associated with poor prognosis in oncology but showcasing impressive results in melanoma patients. This review article provides a comprehensive synthesis of the most recent knowledge on staging and prognostic factors while highlighting emerging therapeutic modalities, with a particular focus on neoadjuvant and adjuvant strategies, notably immunotherapy and targeted therapies, including the ongoing trials.
Insights
Melanoma treatments are advancing with immunotherapy and targeted therapies improving outcomes for all stages. Novel approaches show promise, especially for brain metastasis, offering new hope for patients.
Area of Science:
- Oncology
- Dermatology
- Cancer Research
Background:
- Melanoma is a prevalent and aggressive skin cancer with a high risk of metastasis.
- Traditional treatments face challenges due to melanoma's complex pathogenesis.
- Recent understanding of tumor biology drives new therapeutic strategies.
Purpose of the Study:
- To synthesize current knowledge on melanoma staging and prognostic factors.
- To highlight emerging therapeutic modalities, focusing on neoadjuvant and adjuvant treatments.
- To review advancements in targeted therapies and immunotherapy for melanoma.
Main Methods:
- Comprehensive literature review of recent advancements in melanoma treatment.
- Analysis of clinical outcomes across different disease stages (neoadjuvant, adjuvant, metastatic).
- Focus on novel therapeutic strategies including immunotherapy and targeted agents.
Main Results:
- Immunotherapy and tyrosine kinase inhibitors show significant potential to improve outcomes.
- Groundbreaking progress has been made in treating melanoma brain metastasis.
- Neoadjuvant and adjuvant strategies, including immunotherapy, are demonstrating efficacy.
Conclusions:
- Targeted therapies and immunotherapy represent a paradigm shift in melanoma management.
- Emerging treatments offer improved prognosis, particularly for advanced and metastatic disease.
- Ongoing trials continue to explore novel therapeutic avenues for melanoma.
Related Concept Videos
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:27Tumor Immunotherapy
01:21Cancer Survival Analysis
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...